Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Burkitt Lymphoma 6Lymphoma, B-Cell 5Lymphoma 5Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Lymphoma, Non-Hodgkin 2Hematologic Neoplasms 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Follicular 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Leukemia 1Blast Crisis 1

Interventions

Rituximab 40Cyclophosphamide 29Etoposide 15Doxorubicin 14Vincristine 13Prednisone 13ibrutinib 10fludarabine 10fludarabine phosphate 8Cytarabine 8Mycophenolic Acid 7Bortezomib 7Lenalidomide 6Carmustine 6pembrolizumab 5Peripheral Blood Stem Cell Transplantation 5Melphalan 5Inotuzumab Ozogamicin 5Whole-Body Irradiation 4Tacrolimus 4Carboplatin 4CT-P10 4Brentuximab Vedotin 4Antilymphocyte Serum 4tositumomab I-131 3tocilizumab 3tazemetostat 3obinutuzumab 3idelalisib 3etoposide phosphate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × Lymphoma, B-Cell × Inotuzumab Ozogamicin × Clear all
NCT01055496 2019-08-02

Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma

Pfizer

Phase 1 Completed
103 enrolled 20 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT00724971 2019-03-15

Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab

Pfizer

Phase 1 Completed
10 enrolled 13 charts
Lymphoid

Lymphoma, B-Cell

NCT00073749 2018-12-17

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

Pfizer

Phase 1 Completed
79 enrolled 24 charts
Lymphoid

Lymphoma, Lymphoma, B-Cell

NCT00299494 2018-03-08

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

Pfizer

Phase 1/2 Completed
119 enrolled 60 charts
Lymphoid

Lymphoma, Lymphoma, B-Cell

NCT00867087 2017-12-05

Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Pfizer

Phase 2 Completed
64 enrolled 15 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡